Repare Therapeutics (RPTX) Price & Analysis

Compare

434 Followers

RPTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.89 - $4.07

Previous CloseN/A

Volume283.97K

Average Volume (3M)505.23K

Market Cap

$64.77M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.21

Next Earnings

Aug 06, 2025

EPS Estimate

-0.56

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.71

Shares Outstanding42,891,403

10 Day Avg. Volume203,526

30 Day Avg. Volume505,233

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$1.50

Price Target Upside-0.66% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Financial StabilityRepare's cash runway extends into late-2027, providing financial stability and possibly further extended by the new agreement.

Pipeline DevelopmentPre-clinical data presented at AACR demonstrates RP-1664 efficacy in breast cancer models.

Strategic PartnershipsRepare announced entry into a worldwide, exclusive license agreement with Debiopharm around lunreserb, yielding $10M upfront and up to $257M in potential milestones.

Bears Say

Financial PerformanceRepare reported a Q1 net loss of $30MM.

Net LossesRepare Therapeutics reported a net loss of $28.7 million for Q4 and $84.7 million for the fiscal year 2024.

Restructuring ChallengesThe leadership transition comes in the wake of a previously-announced restructuring that includes a 75% workforce reduction and other leadership departures.

Repare Therapeutics News

Closing Bell Movers: Victory Capital gains on S&P 400 inclusion

In the opening 90 minutes of the evening session, U.S. equity futures are down slightly with a 0.2%...

17d ago

BHF

BLK

Repare Therapeutics enters licensing pact with Debiopharm for Lunresertib

Repare Therapeutics (RPTX) announced it has entered into an exclusive worldwide licensing agreement with Debiopharm International S.A., a...

17d ago

RPTX

Repare Therapeutics Signs Licensing Deal with Debiopharm

An announcement from Repare Therapeutics ( ($RPTX) ) is now available. On July 15, 2025, Repare Therapeutics entered...

16d ago

RPTX

Repare Therapeutics Updates Severance Benefits for Executives

Repare Therapeutics ( ($RPTX) ) has issued an announcement. On June 13, 2025, Repare Therapeutics Inc.’s Compensation Committee...

1M ago

RPTX

Repare Therapeutics Holds Annual Shareholder Meeting

Repare Therapeutics ( ($RPTX) ) has shared an announcement. On June 17, 2025, Repare Therapeutics held its Annual...

2M ago

RPTX

Repare Therapeutics Strengthens Leadership with New Executive Appointment

Repare Therapeutics ( ($RPTX) ) just unveiled an update. Repare Therapeutics Inc. has announced an amendment to its...

2M ago

RPTX

Repare Therapeutics Advances Strategic Partnerships and Clinical Trials Amid Financial Updates

Repare Therapeutics ( ($RPTX) ) has shared an announcement. Repare Therapeutics has announced a strategic partnership with DCx...

3M ago

RPTX

Repare Therapeutics reports Q1 EPS (71c) vs 30c last year

“During the first quarter of 2025 we continued our efforts to create long-term value for our shareholders via...

3M ago

RPTX

Repare Therapeutics expects cash to fund operations through 2027

Cash, cash equivalents and marketable securities: Cash, cash equivalents and marketable securities as of March 31, 2025 were...

3M ago

RPTX

RPTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Repare Therapeutics Inc (RPTX) is scheduled to report 1st quarter earnings on 05/13/2025. Regarding Q1 estimates, Wall Street...

3M ago

RPTX

Repare Therapeutics Out-Licenses Platforms to DCx Biotherapeutics

Repare Therapeutics ( ($RPTX) ) has shared an update. On May 1, 2025, Repare Therapeutics announced an agreement...

3M ago

RPTX

Cathie Wood Snags Robinhood Stock (HOOD) and GitLab (GTLB) as Markets Slide

Cathie Wood, the founder and CEO of ARK Invest and one of the most closely watched growth investors...

4M ago

GTLB

HOOD

Repare Therapeutics Announces Leadership Changes in 2025

Repare Therapeutics ( ($RPTX) ) has provided an announcement. On March 31, 2025, Repare Therapeutics announced significant leadership...

4M ago

RPTX

Repare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeeds

Repare Therapeutics (RPTX) announced that Steve Forte, Executive Vice President and CFO, has been appointed as President and...

4M ago

RPTX

RPTX FAQ

What was Repare Therapeutics Inc’s price range in the past 12 months?

Repare Therapeutics Inc lowest stock price was $0.89 and its highest was $4.07 in the past 12 months.

What is Repare Therapeutics Inc’s market cap?

Repare Therapeutics Inc’s market cap is $64.77M.

When is Repare Therapeutics Inc’s upcoming earnings report date?

Repare Therapeutics Inc’s upcoming earnings report date is Aug 06, 2025 which is in 4 days.

How were Repare Therapeutics Inc’s earnings last quarter?

Repare Therapeutics Inc released its earnings results on May 13, 2025. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.655 by -$0.055.

Is Repare Therapeutics Inc overvalued?

According to Wall Street analysts Repare Therapeutics Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Repare Therapeutics Inc pay dividends?

Repare Therapeutics Inc does not currently pay dividends.

What is Repare Therapeutics Inc’s EPS estimate?

Repare Therapeutics Inc’s EPS estimate is -0.56.

How many shares outstanding does Repare Therapeutics Inc have?

Repare Therapeutics Inc has 42,891,403 shares outstanding.

What happened to Repare Therapeutics Inc’s price movement after its last earnings report?

Repare Therapeutics Inc reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.655. Following the earnings report the stock price went down -9.091%.

Which hedge fund is a major shareholder of Repare Therapeutics Inc?

Currently, no hedge funds are holding shares in RPTX

Repare Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-71.64%

Trailing 12-Months

Asset Growth

-45.26%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Repare Therapeutics Inc

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

Repare Therapeutics (RPTX) Earnings & Revenues

RPTX Earnings Data >

RPTX Stock 12 Month Forecast

Average Price Target

$1.50

▼(-0.66%Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","4":"$4"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1,2,3,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.42,1.426153846153846,1.4323076923076923,1.4384615384615385,1.4446153846153846,1.4507692307692308,1.456923076923077,1.463076923076923,1.4692307692307691,1.4753846153846153,1.4815384615384615,1.4876923076923076,1.4938461538461538,{"y":1.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.42,1.426153846153846,1.4323076923076923,1.4384615384615385,1.4446153846153846,1.4507692307692308,1.456923076923077,1.463076923076923,1.4692307692307691,1.4753846153846153,1.4815384615384615,1.4876923076923076,1.4938461538461538,{"y":1.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.42,1.426153846153846,1.4323076923076923,1.4384615384615385,1.4446153846153846,1.4507692307692308,1.456923076923077,1.463076923076923,1.4692307692307691,1.4753846153846153,1.4815384615384615,1.4876923076923076,1.4938461538461538,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.48,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.33,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.41,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.91,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >